KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Other financing activities (2020 - 2023)

GoodRx Holdings (GDRX) has disclosed Other financing activities for 4 consecutive years, with $3.7 million as the latest value for Q1 2023.

  • Quarterly Other financing activities fell 61.2% to $3.7 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 126.79% year-over-year, with the annual reading at $2.7 million for FY2024, N/A changed from the prior year.
  • Other financing activities hit $3.7 million in Q1 2023 for GoodRx Holdings, up from -$17.6 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $81.7 million in Q4 2020 to a low of -$17.6 million in Q4 2022.
  • Historically, Other financing activities has averaged $13.1 million across 4 years, with a median of $7.1 million in 2022.
  • Biggest five-year swings in Other financing activities: surged 493.62% in 2021 and later tumbled 80.37% in 2022.
  • Year by year, Other financing activities stood at $81.7 million in 2020, then plummeted by 79.62% to $16.7 million in 2021, then crashed by 205.4% to -$17.6 million in 2022, then soared by 121.13% to $3.7 million in 2023.
  • Business Quant data shows Other financing activities for GDRX at $3.7 million in Q1 2023, -$17.6 million in Q4 2022, and $3.3 million in Q3 2022.